Is Zimmer Biomet Holdings, Inc. (ZBH) The Top Falling Stock with Unusual Volume?

We recently published a list of Top 20 Falling Stocks with Unusual Volume. In this article, we are going to take a look at where Zimmer Biomet Holdings, Inc. (NYSE:ZBH) stands against other top falling stocks with unusual volume.

Uncertainty around tariffs and macroeconomic conditions has dented investor confidence, resulting in stock prices falling. While some stocks have come under pressure due to the above two reasons, others have simply followed the market direction or have dipped for company-specific reasons.

Regardless of the reasons for stocks going down, falling stocks provide an opportunity for fresh investors to get in at good prices. Once the risks subside, these stocks usually recover quickly as well. We decided to uncover these stocks and see if it makes sense to put money in them to take advantage of the ongoing market turmoil.

To come up with our list of top 20 stocks falling with unusual volume, we looked at stocks over $300 million in market cap, their one-week performance, and used relative volume to detect the unusual volume activity.

Relative volume compares the daily volume to the three-month average trading volume of the stock, making it easy to detect spikes in volume. These spikes usually signal something important is happening, which, when combined with falling prices, becomes a red flag that investors can’t ignore.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) is a medical technology company. It manufactures, markets, and designs orthopedic reconstructive products. The company provides bone cement, technology and data, and surgical products. It serves neurosurgeons, stocking distributors, orthopedic surgeons, healthcare dealers, hospitals, and other specialists.

The medical firm’s stock is down 4.24% in a week on a relative volume of 2.14. The stock has been tumbling since the start of the month due to tariff fears, but the market seems to have overreacted. Earlier this week, Barclays pointed out ZBH as one of the least affected stocks from Trump’s tariffs. News on other fronts has also been positive.

The U.S. FDA cleared the company’s Persona Revision SoluTion Femur last month. This is a new knee implant component designed for patients with metal sensitivities. According to Zimmer Biomet Holdings, Inc. (NYSE:ZBH), Persona Revision SoluTion Femur is anticipated to launch in the U.S. in Q3 2025.

The firm’s president, Joe Urban, mentioned:

“We are pleased to expand our proprietary surface-hardening technology into the revision knee space with FDA clearance of the Persona Revision SoluTion Femur, the first metal alternative option for those with certain metal sensitivities.”

Based on the company’s provided outlook, it plans to introduce over 50 new products in the next 3 years. Anticipated constant currency revenue growth is in the range of 3% to 5%. Management predicts an improved margin and revenue in the latter half of the year. This growth trajectory is expected to be well complemented by operational improvements and new product ramp-ups, making the current dip attractive.

Overall, ZBH ranks 19th on our list of top falling stocks with unusual volume. While we acknowledge the potential of ZBH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than ZBH but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.